Pembrolizumab-Induced Primary Adrenal Insufficiency: A Rare But Life-Threatening Endocrine irAE

Authors

Syeda Sarah Raza, Shifa International Hospital, PakistanFollow
Mehr A. Orakzai, Khyber Medical College, PeshawarFollow
Abdullah A. Orakzai, Rochester Regional Health SystemFollow

Author Credentials

Syeda Sarah Raza, MD, MBBS, Medical Officer Hematology & Oncology, Shifa International Hospital

Abdullah Ahmad Orakzai, MD, MBBS, Resident Internal Medicine, Rochester General Hospital,

Mehr Ahmad Orakzai, Medical Officer, Khyber Teaching Hospital, Peshawar, Pakistan

Author ORCID Identifier

Syeda Sarah Raza: https://orcid.org/0009-0002-0303-0494

Abdullah A Orakzai: https://orcid.org/0000-0002-9209-0116

Abstract

Pembrolizumab, a PD-1 checkpoint inhibitor, is widely used in the treatment of various malignancies. While it improves overall survival, it can lead to immune-related adverse events (irAEs), including rare endocrine disorders such as primary adrenal insufficiency (PAI). We present a case of PAI induced by Pembrolizumab in a 75-year-old man, emphasizing the importance of early recognition and timely management.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Recommended Citation

Raza S, Orakzai MA, Orakzai AA. Pembrolizumab-Induced Primary Adrenal Insufficiency: A Rare But Life-Threatening Endocrine irAE. Advances in Clinical Medical Research and Healthcare Delivery. 2026; 6(1):34-36. doi: 10.53785/2769-2779.1341.